NCT01020526

Brief Summary

The main purpose of this study is to evaluate the long-term safety of pregabalin in adolescent patients who participated in the previous fibromyalgia study (A0081180) and who wish to recieve open-label pregabalin

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Sep 2010

Longer than P75 for phase_4

Geographic Reach
3 countries

26 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 23, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 25, 2009

Completed
9 months until next milestone

Study Start

First participant enrolled

September 1, 2010

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

July 1, 2016

Completed
Last Updated

January 28, 2021

Status Verified

May 1, 2016

Enrollment Period

4.8 years

First QC Date

November 23, 2009

Results QC Date

May 24, 2016

Last Update Submit

January 26, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline in Pain Numeric Rating Scale by Week

    The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain. Participants chose the number that best described the pain during the last week. Negative change indicates improvement.

    Baseline, Weeks 3, 8, 16, 24 and Last Visit.

Study Arms (1)

Pregabalin

EXPERIMENTAL
Drug: pregabalin

Interventions

Oral capsule 75-450 mg/day

Pregabalin

Eligibility Criteria

Age12 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may not qualify if:

  • Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia study A0081180 which was determined to be related to the study medication by the investigator or sponsor.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (26)

Childrens Hospital Los Angeles

Los Angeles, California, 90027, United States

Location

Apex Research Institute

Santa Ana, California, 92705, United States

Location

Florida Medical Center & Research

Miami, Florida, 33142, United States

Location

Harmony Clinical Research, Incorporated

North Miami Beach, Florida, 33162, United States

Location

Rheumatology Associates of Central Florida, PA

Orlando, Florida, 32806, United States

Location

Medical Research & Health Education Foundation, Inc.

Columbus, Georgia, 31909, United States

Location

Kosair Charities Pediatric Clinical Research Unit

Louisville, Kentucky, 40202, United States

Location

Kosair Children's Hospital

Louisville, Kentucky, 40202, United States

Location

University of Louisville

Louisville, Kentucky, 40202, United States

Location

University Pediatric Rheumatology of Kentucky, LLC

Louisville, Kentucky, 40202, United States

Location

University of Massachusetts Memorial Medical Center Department of Pediatrics

Worcester, Massachusetts, 01655, United States

Location

Akron Children's Hospital

Akron, Ohio, 44308, United States

Location

Akron Children's Hospital-Mahoning Valley

Boardman, Ohio, 44512, United States

Location

Akron Children's Hospital

Boardman, Ohio, 44512, United States

Location

University of Cincinnati Department of Psychiatry and Behavioral Neuroscience

Cincinnati, Ohio, 45219, United States

Location

Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

Location

The Research Institute at Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

Location

Medical University of South Carolina, Pediatric Rheumatology

Charleston, South Carolina, 29425, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Carolina Research Center

Myrtle Beach, South Carolina, 29572, United States

Location

Fatigue Consultation Clinic

Salt Lake City, Utah, 84102, United States

Location

Bioregeneracni a rehabilitacni centrum

Říčany, 25101, Czechia

Location

Krishna Institute of Medical Sciences Ltd

Secunderabad, Andhra Pradesh, 500 003, India

Location

Mallikatta Neuro Center

Mangalore, Karnataka, 575002, India

Location

Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics

Nagpur, Maharashtra, 440010, India

Location

King George's Medical University

Lucknow, Uttar Pradesh, 226 018, India

Location

Related Publications (1)

  • Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, Bhadra-Brown P, Clair A, Chew ML, Scavone J; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016 Jul 30;14(1):46. doi: 10.1186/s12969-016-0106-4.

Related Links

MeSH Terms

Conditions

Fibromyalgia

Interventions

Pregabalin

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Results Point of Contact

Title
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer, Inc.

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 23, 2009

First Posted

November 25, 2009

Study Start

September 1, 2010

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

January 28, 2021

Results First Posted

July 1, 2016

Record last verified: 2016-05

Locations